CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA

Livio Pagano, Morena Caira, Caterina Giovanna Valentini, Luana Fianchi
  • Livio Pagano
    Catholic University ,Rome, Italy
  • Caterina Giovanna Valentini
    Affiliation not present
  • Luana Fianchi
    Affiliation not present

Abstract

Burkitt’s lymphoma is a highly aggressivemature B-cell neoplasm consisting of endemic, sporadic, andimmunodeficiency-associated variants, that share manymorphologic and immunophenotypic features. It is characterized by a high proliferation rate and propensity for extranodal sites such as gastrointestinal tract and reproductive organs. Brief-duration, high-intensity chemotherapy regimensincluding aggressive central nervous system prophylaxis havehad remarkable success in the treatment of this disease in the sporadic form, with very high complete remission rate and overall survival  in adults. Although Burkitt's lymphoma is extremely chemosensitive, biologically targeted therapiesshould be developed, because current treatment options are suboptimalfor patients with poor prognostic features or with relapsed disease.

Keywords

Burkitt lymphoma , Chemotherapy , Immunotherapy

Full Text:

PDF
HTML
Submitted: 2014-06-11 11:44:33
Published:
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
79

Views:
PDF
80
HTML
1819

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185